"Candidiasis, Oral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed)
| Descriptor ID |
D002180
|
| MeSH Number(s) |
C01.703.160.180 C07.465.130
|
| Concept/Terms |
Candidiasis, Oral- Candidiasis, Oral
- Candidiases, Oral
- Oral Candidiases
- Oral Candidiasis
- Thrush
- Moniliasis, Oral
- Moniliases, Oral
- Oral Moniliases
- Oral Moniliasis
|
Below are MeSH descriptors whose meaning is more general than "Candidiasis, Oral".
Below are MeSH descriptors whose meaning is more specific than "Candidiasis, Oral".
This graph shows the total number of publications written about "Candidiasis, Oral" by people in this website by year, and whether "Candidiasis, Oral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 3 | 0 | 3 |
| 1999 | 3 | 0 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 4 | 1 | 5 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Candidiasis, Oral" by people in Profiles.
-
Vila TV, Chaturvedi AK, Rozental S, Lopez-Ribot JL. In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother. 2015 Dec; 59(12):7611-20.
-
Yadev NP, Murdoch C, Saville SP, Thornhill MH. Evaluation of tissue engineered models of the oral mucosa to investigate oral candidiasis. Microb Pathog. 2011 Jun; 50(6):278-85.
-
S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 2005 Jun; 22(2):83-92.
-
Tirado G, Jove G, Kumar R, Noel RJ, Reyes E, Sepulveda G, Yamamura Y, Kumar A. Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female. AIDS Res Hum Retroviruses. 2004 Jun; 20(6):684-6.
-
Li X, Brown N, Chau AS, L?pez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan; 53(1):74-80.
-
Leigh JE, Steele C, Wormley F, Fidel PL. Salivary cytokine profiles in the immunocompetent individual with Candida-associated denture stomatitis. Oral Microbiol Immunol. 2002 Oct; 17(5):311-4.
-
Martinez M, L?pez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002 Sep; 40(9):3135-9.
-
Perea S, L?pez-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002 Jun; 46(6):1695-703.
-
Bachmann SP, Patterson TF, L?pez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002 Jun; 40(6):2228-30.
-
Mart?nez M, L?pez-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002 Mar; 49(3):515-24.